{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:56:29Z","timestamp":1792788989462,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ard.2025.10.015","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T21:04:54Z","timestamp":1763067894000},"page":"921-931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of clofutriben, a selective 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts"],"prefix":"10.1016","volume":"85","author":[{"given":"Frank","family":"Buttgereit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Everding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Andreica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert L","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Schuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Weyand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S.","family":"Czerwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4400-5669","authenticated-orcid":false,"given":"David A.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.10.015_bib0001","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1210\/er.2003-0031","article-title":"11b-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response","volume":"25","author":"Tomlinson","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ard.2025.10.015_bib0002","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.2337\/diabetes.53.8.2051","article-title":"Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11b-hydroxysteroid Dehydrogenase (11 -HSD) type 1 pathway","volume":"53","author":"Basu","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.ard.2025.10.015_bib0003","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/diabetes.54.5.1364","article-title":"The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans","volume":"54","author":"Andrew","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.ard.2025.10.015_bib0004","first-page":"57","article-title":"Absence of cushingoid phenotype in a patient with Cushing\u2019s disease due to defective cortisone to cortisol conversion","volume":"87","author":"Tomlinson","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ard.2025.10.015_bib0005","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1507\/endocrj.K08E-008","article-title":"A case of cortisol producing adrenal adenoma without phenotype of cushing\u2019s syndrome due to impaired 11\u03b2-hydroxysteroid dehydrogenase 1 activity","volume":"55","author":"Arai","year":"2008","journal-title":"Endocr J"},{"key":"10.1016\/j.ard.2025.10.015_bib0006","doi-asserted-by":"crossref","first-page":"luae158","DOI":"10.1210\/jcemcr\/luae158","article-title":"Impaired 11\u03b2-HSD1 activity in a male patient with cushing disease resulting in lack of the full cushingoid phenotype","volume":"2","author":"Weber","year":"2024","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.ard.2025.10.015_bib0007","doi-asserted-by":"crossref","first-page":"E2482","DOI":"10.1073\/pnas.1323681111","article-title":"11\u03b2-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess","volume":"111","author":"Morgan","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ard.2025.10.015_bib0008","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/annrheumdis-2020-218493","article-title":"Local steroid activation is a critical mediator of the anti-inflammatory actions of therapeutic glucocorticoids","volume":"80","author":"Fenton","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.015_bib0009","first-page":"2056","article-title":"Glycyrrhizin could reduce ocular hypertension induced by triamcinolone acetonide in rabbits","volume":"17","author":"Song","year":"2011","journal-title":"Mol Vis"},{"key":"10.1016\/j.ard.2025.10.015_bib0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1530\/JOE-16-0011","article-title":"Glucocorticoids and 11\u03b2-HSD1 are major regulators of intramyocellular protein metabolism","volume":"229","author":"Morgan","year":"2016","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ard.2025.10.015_bib0011","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1210\/en.2017-00607","article-title":"Topical 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibition corrects cutaneous features of systemic glucocorticoid excess in female mice","volume":"159","author":"Tiganescu","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.ard.2025.10.015_bib0012","doi-asserted-by":"crossref","first-page":"e3865","DOI":"10.1210\/clinem\/dgab450","article-title":"An open-label phase I\/IIa clinical trial of 11\u03b2-HSD1 inhibitor for Cushing\u2019s syndrome and autonomous cortisol secretion","volume":"106","author":"Oda","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ard.2025.10.015_bib0013","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41467-023-36541-w","article-title":"11\u03b2-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial","volume":"14","author":"Othonos","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ard.2025.10.015_bib0014","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/cts.12618","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ASP3662, a novel 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor, in healthy young and elderly subjects","volume":"12","author":"Bellaire","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ard.2025.10.015_bib0015","article-title":"The 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor SPI-62 prevents morbidity in a mouse model of Cushing\u2019s syndrome","author":"Pan","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ard.2025.10.015_bib0016","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.015_bib0017","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s40262-023-01278-8","article-title":"Population target-mediated pharmacokinetic\/pharmacodynamic modeling to evaluate SPI-62 exposure and hepatic 11\u03b2-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition in healthy adults","volume":"62","author":"Wu","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ard.2025.10.015_bib0018","unstructured":"Katz DA, Methods for administering corticosteroids. US Patent 12, 220, 412 https:\/\/patents.google.com\/patent\/US12220412B2\/en?oq=us12220412."},{"key":"10.1016\/j.ard.2025.10.015_bib0019","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.10.015_bib0020","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/BF02556669","article-title":"Establishment of the relative antiinflammatory potency of deflazacort and prednisone in polymyalgia rheumatica","volume":"41","author":"Lund","year":"1987","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ard.2025.10.015_bib0021","unstructured":"Thiele K, Albrecht K, Alexander T, Aringer M, Eidner T, Henes J, et al. National database of the German Collaborative Arthritis Centres\u2014Trends in health care provision 2024. German Rheumatism Research Centre Berlin.https:\/\/refubium.fu-berlin.de\/bitstream\/handle\/fub188\/45498\/National_Database_Trends_2024.pdf"},{"key":"10.1016\/j.ard.2025.10.015_bib0022","doi-asserted-by":"crossref","first-page":"G25","DOI":"10.1093\/ejendo\/lvae029","article-title":"European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and therapy of glucocorticoid-induced adrenal insufficiency","volume":"190","author":"Beuschlein","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ard.2025.10.015_bib0023","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","article-title":"Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis","volume":"41","author":"Floris","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.10.015_bib0024","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1093\/rheumatology\/kead088","article-title":"Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis","volume":"62","author":"Palmowski","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.ard.2025.10.015_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152349","article-title":"Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: a systematic review and meta-analysis of randomised trials","volume":"64","author":"Palmowski","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.10.015_bib0026","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13075-019-1972-1","article-title":"11\u03b2-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy","volume":"21","author":"Fenton","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.10.015_bib0027","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/j.1538-7836.2010.04034.x","article-title":"Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors","volume":"8","author":"van Zaane","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ard.2025.10.015_bib0028","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood-2005-01-0186","article-title":"Expression of 11\u03b2-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells","volume":"106","author":"Freeman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ard.2025.10.015_bib0029","doi-asserted-by":"crossref","first-page":"879","DOI":"10.4049\/jimmunol.174.2.879","article-title":"The expression of 11\u03b2-hydroxysteroid dehydrogenase type I by lymphocytes provides a novel means for intracrine regulation of glucocorticoid activities","volume":"174","author":"Zhang","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2025.10.015_bib0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/en.2011-1398","article-title":"11\u03b2-hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice","volume":"153","author":"Coutinho","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.ard.2025.10.015_bib0031","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/cvr\/cvq149","article-title":"Improved heart function follows enhanced inflammatory cell recruitment and angiogenesis in 11bHSD1-deficient mice post-MI","volume":"88","author":"McSweeney","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ard.2025.10.015_bib0032","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbi.2017.11.015","article-title":"11\u03b2-hydroxysteroid dehydrogenase-1 deficiency alters brain energy metabolism in acute systemic inflammation","volume":"69","author":"Verma","year":"2018","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.ard.2025.10.015_bib0033","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1210\/jc.2004-2379","article-title":"Effects of short-term glucocorticoids on cardiovascular biomarkers","volume":"90","author":"Brotman","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ard.2025.10.015_bib0034","unstructured":"Zemskova M. FDA Clinical Review of NDA. 202107:2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202107Orig1s000MedR.pdf"},{"key":"10.1016\/j.ard.2025.10.015_bib0035","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ard.2025.10.015_bib0036","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/cpdd.5","article-title":"Clinical safety, pharmacokinetics, and pharmacodynamics of the 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers and elderly adults","volume":"2","author":"Liu","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.ard.2025.10.015_bib0037","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3899\/jrheum.161109","article-title":"The OMERACT core domain set for outcome measures for clinical trials in polymyalgia rheumatica","volume":"44","author":"Mackie","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.10.015_bib0038","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1530\/EJE-11-0751","article-title":"Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals","volume":"166","author":"Kauh","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.10.015_bib0039","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ard.2025.05.081","article-title":"OP0058\u2005Effects of clofutriben, a selective 11\u00df-hydroxysteroid dehydrogenase type 1 inhibitor, on efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica","volume":"84","author":"Buttgereit","year":"2025","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725044541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725044541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:02:50Z","timestamp":1792267370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725044541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0003496725044541"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.10.015","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of clofutriben, a selective 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}